Biologic Therapy for Psoriasis PDF Download
Are you looking for read ebook online? Search for your book and save it on your Kindle device, PC, phones or tablets. Download Biologic Therapy for Psoriasis PDF full book. Access full book title Biologic Therapy for Psoriasis by Nicholas Brownstone. Download full books in PDF and EPUB format.
Author: Nicholas Brownstone
Publisher: Springer Nature
ISBN: 3030929388
Category : Medical
Languages : en
Pages : 153
Get Book
Book Description
Biologic therapy is a treatment that strives to modulate a patient's immune system to fight a given disease. In psoriasis, a skin disorder that is partly caused by a dysregulated immune system resulting in well-demarcated red areas of the skin with white scales, biologic therapy has the potential to vastly improve upon patient outcomes by minimizing the symptoms of this disease while maximizing the safety profile of the therapy. This book offers an up-to-date and comprehensive review on biologic therapy for the treatment of psoriasis. With over 10 FDA approved biologic agents for psoriasis (with more in the pipeline), confusion exists among providers regarding which agent is best for a particular patient. Chapters cover all FDA approved psoriasis biologic agents (including pipeline agents) for use in pediatric, adult, and geriatric patients. This book is unique in that it will not only cover cutting edge treatment principles based on the latest research, it will also be one of the most comprehensive reviews of psoriasis biologics in the COVID-19 era. Biologic Therapy for Psoriasis is a must-have resource for board certified dermatologists and rheumatologists, dermatology and rheumatology residents and fellows, dermatology physician assistants, nurse practitioners and medical students. The ultimate goal of this book is to improve patient care by making the busy practicing dermatology provider more adept with these particular therapies.
Author: Nicholas Brownstone
Publisher: Springer Nature
ISBN: 3030929388
Category : Medical
Languages : en
Pages : 153
Get Book
Book Description
Biologic therapy is a treatment that strives to modulate a patient's immune system to fight a given disease. In psoriasis, a skin disorder that is partly caused by a dysregulated immune system resulting in well-demarcated red areas of the skin with white scales, biologic therapy has the potential to vastly improve upon patient outcomes by minimizing the symptoms of this disease while maximizing the safety profile of the therapy. This book offers an up-to-date and comprehensive review on biologic therapy for the treatment of psoriasis. With over 10 FDA approved biologic agents for psoriasis (with more in the pipeline), confusion exists among providers regarding which agent is best for a particular patient. Chapters cover all FDA approved psoriasis biologic agents (including pipeline agents) for use in pediatric, adult, and geriatric patients. This book is unique in that it will not only cover cutting edge treatment principles based on the latest research, it will also be one of the most comprehensive reviews of psoriasis biologics in the COVID-19 era. Biologic Therapy for Psoriasis is a must-have resource for board certified dermatologists and rheumatologists, dermatology and rheumatology residents and fellows, dermatology physician assistants, nurse practitioners and medical students. The ultimate goal of this book is to improve patient care by making the busy practicing dermatology provider more adept with these particular therapies.
Author: Anthony Gaspari
Publisher: Springer Science & Business Media
ISBN: 1848001657
Category : Medical
Languages : en
Pages : 812
Get Book
Book Description
Dermatologists are being asked to understand the pathophysiology of a number of immune-mediated skin diseases. In addition, a number of new products have appeared on the market during the past decade which requires an understanding of the mechanisms of action of these drugs. Dermatologists, however, have no easily understood book to which they can refer to regarding the disease or the drug.
Author: Mark D. Evans
Publisher: Springer Science & Business Media
ISBN: 0387729747
Category : Science
Languages : en
Pages : 228
Get Book
Book Description
This book provides up-to-date coverage of selected topics in nucleic acid oxidation. The topics have been selected to cover everything from basic chemical mechanisms, repair of damage and the biological and pathological meaning of DNA oxidation. The chapters are authored by leading, research active, international experts in the respective topics.
Author: John Y. M. Koo
Publisher: CRC Press
ISBN: 1482215160
Category : Medical
Languages : en
Pages : 422
Get Book
Book Description
Written by experts in the dermatology field, this new fourth edition of Moderate-to-Severe Psoriasis discusses the current use of biologics and other pharmacologic and phototherapy treatments for moderate-to-severe psoriasis. Illustrated with high quality color figures, this standalone text emphasizes safe and effective treatments for the psoriasis patient that are perfect for the dermatologist in daily practice. New to this edition are chapters on day treatment programs, new agents, erythrodermic and pustular psoriasis, special populations, and pharmacogenetics.
Author: Nikhil Yawalkar
Publisher: Karger Medical and Scientific Publishers
ISBN: 3805591519
Category : Medical
Languages : en
Pages : 205
Get Book
Book Description
Treatments for psoriasis, besides affecting the skin, may be associated with various comorbidities (for instance, depression, psoriatic arthritis, Crohn's disease and, in severe psoriasis, metabolic syndrome and cardiovascular diseases), which often presents a therapeutic challenge to physicians.Written by renowned experts, this volume gives a comprehensive overview of psoriasis and its various comorbidities. It describes the treatment modalities for mild and moderate-to-severe psoriasis, including topical, phototherapeutic and conventional systemic treatments (e.g. acitretine, methotrexate and cyclosporine), as well as biological therapies (e.g. alefacept, efalizumab, etanercept, adalimumab and infliximab). The chapters on biological therapies focus on key safety issues. Further chapters focus on such topics as the management of childhood psoriasis and psoriasis in distinctive locations, such as the scalp, face, flexures, palm/soles and nails. Finally, future therapeutic modalities, with the focus on small molecules and potential biological therapies, are discussed.This publication will make significant reading to dermatologists and all physicians dealing with psoriasis, such as general practitioners, psychiatrists, rheumatologists, cardiologists and diabetologists.
Author: John Y. M. Koo
Publisher: CRC Press
ISBN: 1482215098
Category : Medical
Languages : en
Pages : 228
Get Book
Book Description
Using a practical and problem-focused approach, this updated, full-color Third Edition of Mild-to-Moderate Psoriasis equips dermatologists, internists, family practitioners, and residents with a state-of-the-art guide to the clinical management of mild-to-moderate psoriasis.Written by an international team of key opinion leaders, this resource explores new developments in treatments for the condition and provides clinicians with up-to-date strategies for optimal patient management.
Author: Jeffrey M. Weinberg
Publisher: Springer Science & Business Media
ISBN: 3764377240
Category : Medical
Languages : en
Pages : 187
Get Book
Book Description
This volume provides an in-depth overview of the current state of psoriasis and its management. It reviews the clinical manifestations of psoriasis as well as psoriatic arthritis and emphasizes the evolving paradigm of therapy. Coverage includes topical and ultraviolet therapies as well as traditional systemic therapy. In addition, a major focus of the volume is on biologic therapies. New agents in development are also reviewed.
Author: Institute of Medicine
Publisher: National Academies Press
ISBN: 0309225493
Category : Medical
Languages : en
Pages : 432
Get Book
Book Description
The Best Pharmaceuticals for Children Act (BPCA) and the Pediatric Research Equity Act (PREA) were designed to encourage more pediatric studies of drugs used for children. The FDA asked the IOM to review aspects of pediatric studies and changes in product labeling that resulted from BPCA and PREA and their predecessor policies, as well as assess the incentives for pediatric studies of biologics and the extent to which biologics have been studied in children. The IOM committee concludes that these policies have helped provide clinicians who care for children with better information about the efficacy, safety, and appropriate prescribing of drugs. The IOM suggests that more can be done to increase knowledge about drugs used by children and thereby improve the clinical care, health, and well-being of the nation's children.
Author: U. S. Department of Health and Human Services
Publisher: Createspace Independent Pub
ISBN: 9781483925554
Category : Medical
Languages : en
Pages : 174
Get Book
Book Description
Psoriasis is a common, chronic, autoimmune inflammatory skin disease affecting 2 to 3 percent of the worldwide population. The onset of psoriasis predominantly occurs early in adulthood (between the ages of 15 and 25 years) but may affect individuals at any age. The course of psoriasis is marked by chronic and acute phases with a wide variety in relapse and clearance rates. Total health care costs of psoriasis are estimated at $11.25 billion annually. This economic burden, along with the clinically relevant reductions in quality of life experienced by many patients with psoriasis, underscores the need for prompt, effective, and sustained disease management. Among several clinical psoriasis phenotypes, chronic plaque psoriasis is the most frequent, accounting for all but 10 percent of cases. Chronic plaque psoriasis, also known as psoriasis vulgaris, often appears as well-demarcated, erythematous plaques covered with silvery white scales that vary in size up to several centimeters. Different parameters determine disease severity such as the degree of body surface area (BSA) involved, activity of the lesions, the location of lesions in sensitive areas, duration of disease, treatment failures, and the impact on quality of life. While disease localized to nonsensitive areas of skin may be managed effectively with topical agents, patients with more widespread disease often require systemic treatment. The American Academy of Dermatology has published guidelines for the treatment of psoriasis and suggest use of either biologic or nonbiologic systemic agents or phototherapy with ultraviolet B (UVB) or with psoralen plus ultraviolet A (PUVA) therapy in patients with widespread disease. Biologic therapies for psoriasis use genetically engineered drugs that target specific steps in the pathogenesis of psoriasis involving T cells and cytokines . Currently, three biologic TNF-alpha inhibitors (infliximab, etanercept, and adalimumab), and one anti-IL 12/23 agent (ustekinumab) have approval from the Food and Drug Administration (FDA) for psoriasis treatment. Nonbiologic systemic therapies may be effective but can be associated with significant short-term and longterm adverse events (hepatotoxicity, nephrotoxicity, hypertension, dyslipidemia, malignancy, and teratogenicity). Phototherapy, although considered to be one of the safer therapeutic options, requires strict compliance, and the long-term toxicity associated with it includes photocarcinogenesis. The objective of this comparative effectiveness review (CER) is to examine the benefits and harms of biologic systemic agents compared with nonbiologic systemic agents or phototherapy in patients with chronic plaque psoriasis. The Key Questions addressed in this review include: Key Question 1. In patients with chronic plaque psoriasis, what is the comparative effectiveness of systemic biologic agents and systemic nonbiologic agents (between-class comparisons on an individual drug level) or phototherapy when evaluating intermediate (plaque BSA measurement, PASI , Patient's Assessment of Global Improvement, PGA, and individual symptom improvement) and final health outcomes (mortality, HRQoL and other patient-reported outcomes, MACE, diabetes, and psychological comorbidities )? Key Question 2. In patients with chronic plaque psoriasis, what is the comparative safety of systemic biologic agents and systemic nonbiologic agents (between-class comparisons on an individual drug level) or phototherapy (hepatotoxicity, nephrotoxicity, hematologic toxicity, hypertension, alteration in metabolic parameters, injection site reaction, malignancy, infection, and study withdrawal)? Key Question 3. In patients with chronic plaque psoriasis treated with systemic biologic therapy, systemic nonbiologic therapy, or phototherapy, which patient or disease characteristics affect intermediate and final outcomes?
Author: Paul S. Yamauchi
Publisher: Springer
ISBN: 3319668846
Category : Medical
Languages : en
Pages : 574
Get Book
Book Description
Written by leading experts in the field and designed for dermatologists and residents, this book includes evidence-based medicine that underscores the clinical data, as well as practical tips on how to use both biologic and systemic agents in the field of dermatology. In the past decade, there have been several groundbreaking advances in medical dermatology. Novel biologic and systemic agents have been developed to treat inflammatory disorders, including psoriasis and atopic dermatitis, as well as skin malignancies such as melanoma. Biologic and Systemic Agents in Dermatology encompasses these developments by describing the mechanism of action of these various agents and the clinical efficacy and safety to treating these respective disorders. The utilization of biologic and systemic agents in other dermatologic conditions, pharmacoeconomics, pharmacovigilance, and clinical trials outcomes are discussed as well as topics including tumor necrosis, conventional systemic agents for psoriatic disease, and oral agents for atopic dermatitis.
